ArticleTranslational lung cancer research2019

Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: an effective but still broken option.

Biagio Ricciuti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.